Clinical Trial Results:
A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease
Summary
|
|
EudraCT number |
2017-005011-14 |
Trial protocol |
FI NL DE FR |
Global end of trial date |
05 May 2022
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
27 Oct 2023
|
First version publication date |
28 May 2023
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
GE-265-303 Clinical Study Report Lay Summary |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GE-265-303
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03354273 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
GE Healthcare Ltd.
|
||
Sponsor organisation address |
Pollards Wood, Nightingales Lane , Chalfont St Giles, Buckinghamshire, United Kingdom, HP8 4SP
|
||
Public contact |
Medical Director - Francois Tranquart, GE Healthcare Ltd, Francois.tranquart@ge.com
|
||
Scientific contact |
Medical Director - Francois Tranquart, GE Healthcare Ltd, Francois.tranquart@ge.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
05 May 2022
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
05 May 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Assess the diagnostic efficacy (sensitivity and specificity) of Flurpiridaz (18F) Injection positron emission tomography (PET) myocardial perfusion imaging (MPI) in the detection of significant coronary artery disease (CAD), as defined by invasive coronary angiography (ICA), in subjects with suspected CAD.
|
||
Protection of trial subjects |
This study was conducted in full accordance with the Declaration of Helsinki, the Good Clinical Practice: Consolidated Guideline approved by the International Conference on Harmonisation (ICH), and any applicable national and local laws and regulations.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
05 Jun 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 129
|
||
Country: Number of subjects enrolled |
United States: 412
|
||
Country: Number of subjects enrolled |
Finland: 36
|
||
Country: Number of subjects enrolled |
France: 71
|
||
Country: Number of subjects enrolled |
Germany: 3
|
||
Country: Number of subjects enrolled |
Netherlands: 79
|
||
Worldwide total number of subjects |
730
|
||
EEA total number of subjects |
189
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
372
|
||
From 65 to 84 years |
354
|
||
85 years and over |
4
|
|
|||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||
Recruitment details |
This study was conducted at 48 centers in Finland, France, Germany, Netherlands, United States and Canada from 05 June 2018 to 05 May 2022. | ||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||
Screening details |
A total 730 subjects signed informed consent and were enrolled, of these, 604 subjects received greater than or equal to (>=) 1 dose of Flurpiridaz (18F) Injection in this study. | ||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||
Arm title
|
Flurpiridaz (18F): All Subjects | ||||||||||||||||||||||||||||
Arm description |
Subjects received 2 IV boluses of Flurpiridaz (18F) Injection in large peripheral vein:1 at rest then 1 during stress on same day within 60 days prior to ICA. Flurpiridaz(18F) Injection administered were not to exceed total of 14 mCi (520 MBq). Flurpiridaz was administered on Day 1. SPECT agents 99mTc-based myocardial tracers e.g. [99mTc]tetrofosmin or [99mTc]sestamibi were administered per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. Same stress type (pharmacologic or exercise) was used for SPECT and Flurpiridaz(18F) Injection PETMPI. Also, if pharmacological stress was used, same agent, dose of pharmacological stress agent was used for both types of imaging for same subject. Pharmacological stress agents administered according to respective Package Insert or American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Flurpiridaz (18F)
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Flurpiridaz (18F) Injection administered as an intravenous (IV) injection in large peripheral vein 1 at rest then 1 during stress at dose not to exceed a total of 14 mCi (520 MBq) for an individual subject.
|
||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Flurpiridaz (18F): All Subjects
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received 2 IV boluses of Flurpiridaz (18F) Injection in large peripheral vein:1 at rest then 1 during stress on same day within 60 days prior to ICA. Flurpiridaz(18F) Injection administered were not to exceed total of 14 mCi (520 MBq). Flurpiridaz was administered on Day 1. SPECT agents 99mTc-based myocardial tracers e.g. [99mTc]tetrofosmin or [99mTc]sestamibi were administered per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. Same stress type (pharmacologic or exercise) was used for SPECT and Flurpiridaz(18F) Injection PETMPI. Also, if pharmacological stress was used, same agent, dose of pharmacological stress agent was used for both types of imaging for same subject. Pharmacological stress agents administered according to respective Package Insert or American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Flurpiridaz (18F): All Subjects
|
||
Reporting group description |
Subjects received 2 IV boluses of Flurpiridaz (18F) Injection in large peripheral vein:1 at rest then 1 during stress on same day within 60 days prior to ICA. Flurpiridaz(18F) Injection administered were not to exceed total of 14 mCi (520 MBq). Flurpiridaz was administered on Day 1. SPECT agents 99mTc-based myocardial tracers e.g. [99mTc]tetrofosmin or [99mTc]sestamibi were administered per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. Same stress type (pharmacologic or exercise) was used for SPECT and Flurpiridaz(18F) Injection PETMPI. Also, if pharmacological stress was used, same agent, dose of pharmacological stress agent was used for both types of imaging for same subject. Pharmacological stress agents administered according to respective Package Insert or American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. | ||
Subject analysis set title |
SPECT MPI
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
SPECT agents 99mTc-based myocardial tracers, example [99mTc]tetrofosmin or [99mTc]sestamibi were administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. For each subject, the same stress type (pharmacologic or exercise) was used for the SPECT and Flurpiridaz (18F) Injection PET MPI. Also, if pharmacological stress was used, the same agent and the same dose of pharmacological stress agent was used for both types of imaging for the same subject. Pharmacological stress agents were administered according to the respective Package Insert (as applicable) or American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location.
|
|
|||||||||||||||||||||||||
End point title |
Sensitivity and Specificity of Flurpiridaz (18F) Injection Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in the Detection of Significant Coronary Artery Disease (CAD) as Defined by Cardiac Catheterization [1] | ||||||||||||||||||||||||
End point description |
Sensitivity was defined as true positives (TP)/(TP+false negatives [FN]). TP was subjects with abnormal PET MPI and disease positive by truth standard and FN was subjects with normal PET MPI and disease positive by truth standard. Specificity defined as true negatives (TN)/(TN+ false positives [FP]). TN was subjects with normal PET MPI and disease negative by truth standard and FP was subjects with abnormal PET MPI and disease negative by truth standard. Truth standard was presence of CAD as evidenced by presence of stenosis of >=50 percent (%) in >=1 coronary artery or major branch of a coronary artery as determined by quantitative coronary angiography (QCA) analysis. Subjects were considered to have CAD if QCA revealed >=50% stenosis of >=1 major coronary artery or major branch. Sensitivity and specificity were calculated for 3 readers and majority rule using each subject judgement (positive or negative) by at least 2 of 3 readers. MITT population.
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Up to 60 days
|
||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Statistical analyses was performed for 'Flurpiridaz (18F): All Subjects' arm only, and due to database limitation statistical analyses could not to be reported for single arm. Therefore, statistical analyses data for this endpoint is provided in PDF document. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Attachments |
Statistical Data |
||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Sensitivity and Specificity of Flurpiridaz (18F) Injection PET MPI Compared SPECT MPI for All Subjects When the Diagnosis of CAD by ICA Was the Standard of Truth | ||||||||||||||||||||||||||||||||||||
End point description |
Sensitivity: TP/(TP+FN). TP: subjects with abnormal PET MPI and disease positive by truth standard and FN: subjects with normal PET MPI and disease positive by truth standard. Specificity: TN/(TN+ FP). TN: subjects with normal PET MPI and disease negative by truth standard and FP: subjects with abnormal PET MPI and disease negative by truth standard. Truth standard was presence of CAD as evidenced by presence of stenosis of >=50% in >=1 coronary artery or major branch of coronary artery as determined by QCA analysis. Subjects considered to have CAD if QCA revealed >=50% stenosis of >=1 major coronary artery or major branch. Sensitivity, specificity was calculated for 3 readers and majority rule using each subject judgement (positive or negative) by at least 2 of 3 readers. SMITT population. Here, “number of subjects analyzed”= subjects who were analysed for a specific reader (combined sensitivity or specificity) and “n” = subjects who were evaluable for specified categories.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 60 days
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 1: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1156
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [2] | ||||||||||||||||||||||||||||||||||||
P-value |
< 0.0001 [3] | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
14.5
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
6.5 | ||||||||||||||||||||||||||||||||||||
upper limit |
22.4 | ||||||||||||||||||||||||||||||||||||
Notes [2] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1-sided McNemar’s tests. [3] - The hypothesis tests were 1-sided McNemar’s tests with a significance level of 0.025 for sensitivity. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 1: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1156
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [4] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0004 [5] | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
2.4
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-4.9 | ||||||||||||||||||||||||||||||||||||
upper limit |
9.7 | ||||||||||||||||||||||||||||||||||||
Notes [4] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). [5] - The hypothesis tests were 1-sided McNemar’s tests with a significance level of 0.025 for sensitivity. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 2: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1156
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [6] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0002 [7] | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
12.9
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
4.7 | ||||||||||||||||||||||||||||||||||||
upper limit |
21 | ||||||||||||||||||||||||||||||||||||
Notes [6] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. [7] - The hypothesis tests were 1-sided McNemar’s tests with a significance level of 0.025 for sensitivity. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 2: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1156
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [8] | ||||||||||||||||||||||||||||||||||||
P-value |
< 0.0001 [9] | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
4.9
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-2.1 | ||||||||||||||||||||||||||||||||||||
upper limit |
11.8 | ||||||||||||||||||||||||||||||||||||
Notes [8] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). [9] - The hypothesis tests were 1-sided McNemar’s tests with a significance level of 0.025 for sensitivity. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 3: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1156
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [10] | ||||||||||||||||||||||||||||||||||||
P-value |
< 0.0001 [11] | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
13.3
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
6.6 | ||||||||||||||||||||||||||||||||||||
upper limit |
19.9 | ||||||||||||||||||||||||||||||||||||
Notes [10] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. [11] - The hypothesis tests were 1-sided McNemar’s tests with a significance level of 0.025 for sensitivity. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 3: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1156
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [12] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0011 [13] | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
1.2
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-6 | ||||||||||||||||||||||||||||||||||||
upper limit |
8.4 | ||||||||||||||||||||||||||||||||||||
Notes [12] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). [13] - The hypothesis tests were 1-sided McNemar’s tests with a significance level of 0.025 for sensitivity. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Majority Rule: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1156
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [14] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0003 [15] | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
11.6
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
4.1 | ||||||||||||||||||||||||||||||||||||
upper limit |
19.2 | ||||||||||||||||||||||||||||||||||||
Notes [14] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. [15] - The hypothesis tests were 1-sided McNemar’s tests with a significance level of 0.025 for sensitivity. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Majority Rule: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
1156
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [16] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0004 [17] | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
2.1
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-5 | ||||||||||||||||||||||||||||||||||||
upper limit |
9.3 | ||||||||||||||||||||||||||||||||||||
Notes [16] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). [17] - The hypothesis tests were 1-sided McNemar’s tests with a significance level of 0.025 for sensitivity. |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Sensitivity and Specificity of Flurpiridaz (18F) Injection PET MPI Compared SPECT MPI for Female Subjects When the Diagnosis of CAD by ICA Was the Standard of Truth | ||||||||||||||||||||||||||||||||||||
End point description |
Sensitivity: TP/(TP+FN). TP: subjects with abnormal PET MPI and disease positive by truth standard and FN: subjects with normal PET MPI and disease positive by truth standard. Specificity: TN/(TN+ FP). TN: subjects with normal PET MPI and disease negative by truth standard and FP: subjects with abnormal PET MPI and disease negative by truth standard. Truth standard was presence of CAD as evidenced by presence of stenosis of >=50% in >=1 coronary artery or major branch of a coronary artery as determined by QCA analysis. Subjects considered to have CAD if QCA revealed >=50% stenosis of >=1 major coronary artery or major branch. Sensitivity, specificity calculated for 3 readers and majority rule using each subject judgement (positive or negative) by at least 2 of 3 readers. SMITT population. Here, “number of subjects analyzed”= subjects who were analysed for a specific reader (combined sensitivity or specificity) and “n” = subjects who were evaluable for specified categories.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 60 days
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 1: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
376
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [18] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0127 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
24.4
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
5.4 | ||||||||||||||||||||||||||||||||||||
upper limit |
43.4 | ||||||||||||||||||||||||||||||||||||
Notes [18] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 1: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
376
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [19] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0001 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
9.5
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-1.2 | ||||||||||||||||||||||||||||||||||||
upper limit |
20.2 | ||||||||||||||||||||||||||||||||||||
Notes [19] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 2: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
376
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [20] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0195 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
22
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
2.2 | ||||||||||||||||||||||||||||||||||||
upper limit |
41.7 | ||||||||||||||||||||||||||||||||||||
Notes [20] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 2: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
376
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [21] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0004 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
6.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-3.2 | ||||||||||||||||||||||||||||||||||||
upper limit |
16.8 | ||||||||||||||||||||||||||||||||||||
Notes [21] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 3: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
376
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [22] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0174 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
17.1
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
1.7 | ||||||||||||||||||||||||||||||||||||
upper limit |
32.4 | ||||||||||||||||||||||||||||||||||||
Notes [22] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 3: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
376
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [23] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.024 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
0.7
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-9.9 | ||||||||||||||||||||||||||||||||||||
upper limit |
11.3 | ||||||||||||||||||||||||||||||||||||
Notes [23] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Majority Rule: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
376
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [24] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0448 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
17.1
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-1.5 | ||||||||||||||||||||||||||||||||||||
upper limit |
35.6 | ||||||||||||||||||||||||||||||||||||
Notes [24] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Majority Rule: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
376
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [25] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0004 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
6.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-3.4 | ||||||||||||||||||||||||||||||||||||
upper limit |
17 | ||||||||||||||||||||||||||||||||||||
Notes [25] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Sensitivity and Specificity of Flurpiridaz (18F) Injection PET MPI Compared SPECT MPI for Subjects With Body-mass Index (BMI) >=30 Kilograms Per Square Meter (kg/m^2) When the Diagnosis of CAD by ICA Was the Standard of Truth | ||||||||||||||||||||||||||||||||||||
End point description |
Sensitivity:TP/(TP+FN). TP: subjects with abnormal PET MPI and disease positive by truth standard and FN: subjects with normal PET MPI and disease positive by truth standard. Specificity:TN/(TN+ FP). TN: subjects with normal PET MPI and disease negative by truth standard and FP: subjects with abnormal PET MPI and disease negative by truth standard. Truth standard was presence of CAD as evidenced by presence of stenosis of >=50% in >=1 coronary artery or major branch of coronary artery determined by QCA analysis. Subjects considered to have CAD if QCA revealed >=50% stenosis of >=1 major coronary artery or major branch. Sensitivity, specificity calculated for 3 readers and majority rule using each subject judgement (positive or negative) by at least 2 of 3 readers. SMITT population. Here, “number of subjects analyzed”= subjects who were analysed for a specific reader (combined sensitivity or specificity) and “n” = subjects who were evaluable for specified categories.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 60 days
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 1: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
596
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [26] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0116 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
12
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
0 | ||||||||||||||||||||||||||||||||||||
upper limit |
23.9 | ||||||||||||||||||||||||||||||||||||
Notes [26] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 1: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
596
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [27] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0003 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
6.6
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-2.9 | ||||||||||||||||||||||||||||||||||||
upper limit |
16.2 | ||||||||||||||||||||||||||||||||||||
Notes [27] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 2: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
596
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [28] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.1085 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
6.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-5.2 | ||||||||||||||||||||||||||||||||||||
upper limit |
18.9 | ||||||||||||||||||||||||||||||||||||
Notes [28] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 2: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
596
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [29] | ||||||||||||||||||||||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
11.6
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
2.1 | ||||||||||||||||||||||||||||||||||||
upper limit |
21.1 | ||||||||||||||||||||||||||||||||||||
Notes [29] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 3: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
596
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [30] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0017 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
13.7
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
3.8 | ||||||||||||||||||||||||||||||||||||
upper limit |
23.5 | ||||||||||||||||||||||||||||||||||||
Notes [30] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 3: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
596
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [31] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0034 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
2.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-6.6 | ||||||||||||||||||||||||||||||||||||
upper limit |
12.1 | ||||||||||||||||||||||||||||||||||||
Notes [31] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Majority Rule: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
596
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [32] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0641 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
7.7
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-3.6 | ||||||||||||||||||||||||||||||||||||
upper limit |
19 | ||||||||||||||||||||||||||||||||||||
Notes [32] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Majority Rule: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
596
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [33] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.001 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
5
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-4.6 | ||||||||||||||||||||||||||||||||||||
upper limit |
14.6 | ||||||||||||||||||||||||||||||||||||
Notes [33] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Sensitivity and Specificity of Flurpiridaz (18F) Injection PET MPI Compared SPECT MPI for Diabetic Subjects When the Diagnosis of CAD by ICA Was the Standard of Truth | ||||||||||||||||||||||||||||||||||||
End point description |
Sensitivity:TP/(TP+FN). TP: subjects with abnormal PET MPI and disease positive by truth standard and FN: subjects with normal PET MPI and disease positive by truth standard. Specificity:TN/(TN+ FP). TN: subjects with normal PET MPI and disease negative by truth standard and FP: subjects with abnormal PET MPI and disease negative by truth standard. Truth standard was presence of CAD as evidenced by presence of stenosis of >=50% in >=1 coronary artery or major branch of coronary artery determined by QCA analysis. Subjects considered to have CAD if QCA revealed >=50% stenosis of >=1 major coronary artery or major branch. Sensitivity and specificity calculated for 3 readers and majority rule using each subject judgement (positive or negative) by at least 2 of 3 readers. SMITT population. Here, “number of subjects analyzed”= subjects who were analysed for a specific reader (combined sensitivity or specificity) and “n” = subjects who were evaluable for specified categories.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 60 days
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 1: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
388
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [34] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0294 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
11
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-2.6 | ||||||||||||||||||||||||||||||||||||
upper limit |
24.6 | ||||||||||||||||||||||||||||||||||||
Notes [34] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 1: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
388
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [35] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0117 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
3.9
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-8.3 | ||||||||||||||||||||||||||||||||||||
upper limit |
16.1 | ||||||||||||||||||||||||||||||||||||
Notes [35] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 2: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
388
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [36] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.1444 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
6.6
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-7.1 | ||||||||||||||||||||||||||||||||||||
upper limit |
20.3 | ||||||||||||||||||||||||||||||||||||
Notes [36] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 2: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
388
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [37] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0001 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
11.7
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-0.4 | ||||||||||||||||||||||||||||||||||||
upper limit |
23.7 | ||||||||||||||||||||||||||||||||||||
Notes [37] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 3: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
388
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [38] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.044 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
8.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-1.3 | ||||||||||||||||||||||||||||||||||||
upper limit |
18.9 | ||||||||||||||||||||||||||||||||||||
Notes [38] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Reader 3: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
388
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [39] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0022 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
7.8
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-4.8 | ||||||||||||||||||||||||||||||||||||
upper limit |
20.3 | ||||||||||||||||||||||||||||||||||||
Notes [39] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Majority Rule: Sensitivity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
388
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
superiority [40] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.2164 | ||||||||||||||||||||||||||||||||||||
Method |
Mcnemar | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
4.4
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-8.4 | ||||||||||||||||||||||||||||||||||||
upper limit |
17.2 | ||||||||||||||||||||||||||||||||||||
Notes [40] - The test of sensitivity comparison between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a 1-sided McNemar’s test at a significance level of 0.025 using 1- sided McNemar’s tests. |
|||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Majority Rule: Specificity | ||||||||||||||||||||||||||||||||||||
Comparison groups |
Flurpiridaz (18F): All Subjects v SPECT MPI
|
||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
388
|
||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [41] | ||||||||||||||||||||||||||||||||||||
P-value |
= 0.0006 | ||||||||||||||||||||||||||||||||||||
Method |
Nam's RMLE | ||||||||||||||||||||||||||||||||||||
Parameter type |
Difference between PET MPI and SPECT MPI | ||||||||||||||||||||||||||||||||||||
Point estimate |
9.7
|
||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||||||
lower limit |
-2.6 | ||||||||||||||||||||||||||||||||||||
upper limit |
22 | ||||||||||||||||||||||||||||||||||||
Notes [41] - The test of specificity noninferiority between Flurpiridaz (18F) Injection PET MPI and SPECT MPI was performed with a paired test for noninferiority at a 1-sided significance level of 0.025 using Nam’s RMLE method (margin=0.1). |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the time of informed consent to end of follow up (up to 77 days)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Flurpiridaz (18F): Safety Population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received 2 IV boluses of Flurpiridaz (18F) Injection in large peripheral vein:1 at rest then 1 during stress on same day within 60 days prior to ICA. Flurpiridaz(18F) Injection administered were not to exceed total of 14 mCi (520 MBq). Flurpiridaz was administered on Day 1. SPECT agents 99mTcbased myocardial tracers e.g. [99mTc]tetrofosmin or [99mTc]sestamibi were administered per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. Same stress type (pharmacologic or exercise) was used for SPECT and Flurpiridaz(18F) Injection PETMPI. Also, if pharmacological stress was used, same agent, dose of pharmacological stress agent was used for both types of imaging for same subject. Pharmacological stress agents administered according to respective Package Insert or American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards corresponding to study site location. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
03 Aug 2018 |
Amendment 1: Left ventricular ejection fraction (LVEF) <50% was removed from exclusion criterion (8). The purpose of exclusion criterion 8 was to eliminate known/confirmed heart failure. The inclusion of an EF lower limit to specify which subjects should be included did not address this aim. Ejection fraction defines different heart failure phenotypes (e.g. heart failure with preserved, reduced or mid-range ejection fraction) and as such was not relevant to the aim of excluding those with a heart failure diagnosis as a whole. Even if the purpose was to exclude only subjects with reduced EF, the EF of 50% corresponds to ‘normal’ EF when echocardiography is performed but does not correspond to the appropriate value to demark normal and abnormal ejection fractions for other modalities such as SPECT. • Clarification of follow-up period for the study. • Clarification of medicinal products in the study and update of storage and handling conditions for Flurpiridaz (18F) Injection. • Corrections to text to ensure recording of concurrent medications to study completion. • Removal of requirement for drug and alcohol screening. Drug and alcohol abuse screening is useful to address: (1) unique safety concerns associated with potential interactions of IMP with illicit drugs, (2) concerns regarding confounding of an efficacy signal, and (3) concerns that follow-up would be compromised given occult substance abuse. GE Healthcare determined that these concerns were minimal, given: (1) there were no unique concerns regarding drug/illicit drug interactions, particularly given that Flurpiridaz is administered to subjects in one sitting (as opposed to repeatedly) at a tracer dose; |
||||||
03 Aug 2018 |
Amendment 1 (Continued): (2) concerns of confounding the correlation between the anatomical gold standard of the QCA and the PET MPI blinded reads were minimal. It was possible that toxic effects of illicit drugs (such as cocaine) could affect the microvascular function that in turn could lead to perfusion abnormalities as seen on MPI in the absence of significant epicardial coronary stenoses evidenced on QCA. GE Healthcare believed that these discrepancies were likely to be minimal and encountered infrequently, and (3) subjects were already being screened for psychiatric conditions which could impair participation in all study visits (exclusion #12). Substance abuse is an axis II disorder and investigators were counselled to exclude subjects with ongoing drug abuse that may have led to poor compliance in the manual of procedures. Given the short-term follow up of this study, it was unlikely that occult substance abuse (missed as part of the medical history) would frequently impair subject follow up. Since the Sponsor believed that active substance abuse was likely to be rare and to have minimal if any effect on efficacy, no effect on safety, and minimal if any effect on follow-up compliance, the collection of this sensitive health information was not justified. • Guidance regarding use of beta blocker therapy was added. To ensure that the PET and SPECT MPI were conducted according to guidelines and in accordance with standard clinical care, study sites were advised to withhold the beta-blocker when possible for at least 24 hours prior to the stress test. Evidence demonstrates that beta-blockade at the time of stress testing may reduce the sensitivity of MPI. GE Healthcare acknowledged that withholding the beta-blocker might not always be possible due to clinical concerns such as difficult to control hypertension or arrhythmia (as per the guidelines). |
||||||
03 Aug 2018 |
Amendment 1 (Continued): • Clarification that an additional blood sample at screening could be analysed by the local lab to determine if the subject met exclusion criteria. Dependence on central lab results for screening purposes would result in a delay from screening to the earliest performance of in study visits (including the PET or on-study SPECT) of at least 48 hours from the time of the lab draw (in most cases). This delay added a significant hurdle to subject recruitment and retainment in a study where all study visits must occur prior to a prescheduled invasive coronary angiography. In most cases the window between screening and the clinical intracoronary angiography was expected to be less than 7 days. Permitting screening through the use of local labs permitted subject to be screened, enrolled and have a SPECT scan in a minimal amount of time (or even in the same day) with a PET scan following as closely after as doses are available. Central labs results could still be used for screening if local labs were not drawn. The determination of whether to draw local labs for this purpose rested with the investigator and depended on the rapidity with which the study visits occurred (e.g., if the window between screening and ICA was brief, local labs were advised, if this window was more lengthy than local labs were not drawn). Significant discordance between local and central lab results was unlikely since the central and local labs would be drawn in the same sitting at screening. If they did occur the local lab would take precedence for the screening purposes. The safety data set was to use exclusively the central labs to analyse changes in biochemistry, since all patients would systematically have labs analysed centrally at screening and pre- and post-scan timepoints. • Safety reporting for AEs and SAEs was updated and clarified. |
||||||
18 Nov 2019 |
Amendment 02: • Clarification of time points for recording vital signs. • Clarification in text that urine would be collected at pre-treatment time points only. • Medical Director details were updated following a change in personnel. |
||||||
22 Jul 2021 |
Amendment 03: • Editorial correction to clarify that rest and stress SPECT MPI procedures can take place on 2 separate days that do not have to be consecutive. • Correction of typographical error in the description of the semi-quantitative read (exploratory analysis). |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |